The combination of MYC oncogene with CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats)-dependent TP53 knockout was chosen, as the induced HCC tumors were reported to show moderate immune infiltration.11 This evidence concerns the gene TP53 and hepatocellular carcinoma.